PBAC's latest decision on Salbutamol: Recommended with restriction (2020). Considered for Relief of acute bronchospasm in patients with asthma and other obstructive airways diseases. Specifically, a pressurised inhalation formulation with integrated dose counter to assist patients in determining remaining doses and reducing medication wastage.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2014
Submissions
4
2014 → 2020
Eligible population
Adult and paediatric patients with asthma and obstructive airways diseases requiring salbutamol pressurised metered-dose inhalers for acute bronchospasm relief.
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Key trials
Wasserman 2006, Chipps 2017, Kerwin 2017, Lachman 2018, Price 2016, Holt et al 2005
Comparator
salbutamol pressurised inhalation without dose counter (Ventolin MDI, Asmol MDI)
Economic model
Cost-minimisation
ICER note
No formal ICER calculated. This is a cost-minimisation submission for a device modification (addition of dose counter) to an existing PBS-listed medication. The PBAC assessed cost-effectiveness pragmatically via acceptable price premium rather than formal cost-utility analysis.
Submission history
Nov 2014: Recommended · Unrestricted
Nov 2016: Recommended · Restricted
Nov 2019: Recommended with restriction · Restricted
Mar 2020: Recommended with restriction · Restricted